Funded Tech Companies
Memo Therapeutics
Headquartered in Schlieren / Zurich, Memo Therapeutics has funding from Fresenius Medical Care, GF Private Equity Group and Kurma Partners.
Company Overview
Company Name
Memo Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Wagistrasse 27
Schlieren / Zurich, 8952
Switzerland
Schlieren / Zurich, 8952
Switzerland
Phone
Website
Email Address
Company Background Information
Overview
Memo Therapeutics AG ("MTx") is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx' lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection. AntiBKV has successfully completed Phase I with no safety concerns, with Phase II (POC) data expected in H1 2025. MTx' pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus ("CMV"), undisclosed immuno-oncology targets as well as a partnership with Ono Pharmaceutical.
Last Transaction
5/7/2024
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Company Investors
- Fresenius Medical Care
- GF Private Equity Group
- Kurma Partners (Hadrien Bouchez)
- Pureos Bioventures
- Verve Ventures
- Vesalius Biocapital
- Adjuvant Capital
- Schroders Capital
- Redalpine Venture
- Ysios Capital (Thomas Harth)
- Swisscanto Invest
Browse more funded tech companies:
Share this article
About Our Venture Capital Transactions Database
This tech company profile is powered by VentureDeal.com, a market leader in private equity transaction data.
Additional Resources for Entrepreneurs